Barbara Roux1,2,3, Caroline Sirois3,4,5, Marc Simard3, Marie-Eve Gagnon3,4, Marie-Laure Laroche1,2. 1. Centre of Pharmacovigilance and Pharmacoepidemiology, Department of Pharmacology-Toxicology and Centre of Pharmacovigilance, University Hospital of Limoges, Limoges, France. 2. INSERM UMR 1248, Faculty of Medicine, University of Limoges, Limoges, France. 3. Quebec National Institute of Public Health, Quebec, Canada. 4. Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Quebec, Canada. 5. Centre of Excellence on Aging of Quebec, Integrated University Health and Social Services Centres of the Capitale-Nationale, Québec, Canada.
Abstract
AIMS: To assess the 1-year persistence of potentially inappropriate medication (PIM) use and identify associated factors in community-dwelling older adults in Quebec, Canada. METHODS: A population-based cohort study was conducted using the Quebec Integrated Chronic Disease Surveillance System. Individuals insured by the public drug plan and aged ≥66 years who initiated a PIM between 1 April 2014 and 31 March 2015 were followed-up for 1 year. PIMs were identified using the 2015 Beers criteria. One-year persistence of PIM use was defined as continuous treatment with any PIM, without interruption for more than 60 days between prescriptions refills. Poisson regression models were performed to identify factors associated with 1-year persistence of any PIM. RESULTS: In total, 25.1% of PIM initiators were persistent at 1 year. In non-persistent individuals, the median time to PIM discontinuation was 31 days (interquartile range 21-92). Individuals were more persistent at 1 year with antipsychotics (43.9%), long-duration sulphonylureas (40.2%), antiarrhythmics/immediate-release nifedipine (36.5%) and proton pump inhibitors (36.0%). Factors significantly associated with persistence were an increased age, being a man and having a high number of medications and chronic diseases, especially dementia, diabetes and cardiovascular diseases. CONCLUSIONS: One-quarter of community-dwelling older adults are continuously exposed to PIMs. To optimize medication prescribing in the older population, further interventions are needed to limit the use of PIMs most likely to be continued, especially in individuals most at risk of being persistent and also particularly vulnerable to adverse events.
AIMS: To assess the 1-year persistence of potentially inappropriate medication (PIM) use and identify associated factors in community-dwelling older adults in Quebec, Canada. METHODS: A population-based cohort study was conducted using the Quebec Integrated Chronic Disease Surveillance System. Individuals insured by the public drug plan and aged ≥66 years who initiated a PIM between 1 April 2014 and 31 March 2015 were followed-up for 1 year. PIMs were identified using the 2015 Beers criteria. One-year persistence of PIM use was defined as continuous treatment with any PIM, without interruption for more than 60 days between prescriptions refills. Poisson regression models were performed to identify factors associated with 1-year persistence of any PIM. RESULTS: In total, 25.1% of PIM initiators were persistent at 1 year. In non-persistent individuals, the median time to PIM discontinuation was 31 days (interquartile range 21-92). Individuals were more persistent at 1 year with antipsychotics (43.9%), long-duration sulphonylureas (40.2%), antiarrhythmics/immediate-release nifedipine (36.5%) and proton pump inhibitors (36.0%). Factors significantly associated with persistence were an increased age, being a man and having a high number of medications and chronic diseases, especially dementia, diabetes and cardiovascular diseases. CONCLUSIONS: One-quarter of community-dwelling older adults are continuously exposed to PIMs. To optimize medication prescribing in the older population, further interventions are needed to limit the use of PIMs most likely to be continued, especially in individuals most at risk of being persistent and also particularly vulnerable to adverse events.
Authors: Stefan Varga; Matthew Alcusky; Scott W Keith; Sarah E Hegarty; Stefano Del Canale; Marco Lombardi; Vittorio Maio Journal: Br J Clin Pharmacol Date: 2017-08-04 Impact factor: 4.335
Authors: G Edward Miller; Eric M Sarpong; Amy J Davidoff; Eunice Y Yang; Nicole J Brandt; Donna M Fick Journal: Health Serv Res Date: 2016-09-29 Impact factor: 3.402
Authors: C Blais; S Jean; C Sirois; L Rochette; C Plante; I Larocque; M Doucet; G Ruel; M Simard; P Gamache; D Hamel; D St-Laurent; V Emond Journal: Chronic Dis Inj Can Date: 2014-11
Authors: Dana Clarissa Muhlack; Liesa Katharina Hoppe; Christian Stock; Walter E Haefeli; Hermann Brenner; Ben Schöttker Journal: Eur J Clin Pharmacol Date: 2018-08-29 Impact factor: 2.953
Authors: Emily Reeve; Jennifer L Wolff; Maureen Skehan; Elizabeth A Bayliss; Sarah N Hilmer; Cynthia M Boyd Journal: JAMA Intern Med Date: 2018-12-01 Impact factor: 21.873
Authors: Stephanie Stock; Marcus Redaelli; Dusan Simic; Martin Siegel; Frank Henschel Journal: Wien Klin Wochenschr Date: 2014-09-13 Impact factor: 1.704
Authors: Natacha Christina de Araújo; Erika Aparecida Silveira; Brenda Godoi Mota; Rafael Alves Guimarães; Ana Carolina Figueiredo Modesto; Valéria Pagotto Journal: Int J Clin Pharm Date: 2022-07-27